Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.
Among previously untreated patients, the objective response rate (ORR) was 85%, and...
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor...
Study shows frequently used serology test may not detect antibodies that could confirm protection against reinfection of COVID-19
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance...
Cancer care and screenings must remain a priority during COVID-19
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel coronavirus (COVID-19) pandemic. In light of emerging research showing many people are delaying cancer screenings and other health care needs, MD Anderson is reminding both cancer patients and the healthy public that it is safe to keep scheduled appointments for active treatment or routine care.
